Novo Nordisk: Zenagamtide and Etavopivat Shine, but the Market Only Sees CagriSema
Novo Nordisk’s shares continue to trade under a dark cloud, down roughly 46% over the past twelve months…
Novo Nordisk’s Zenagamtide shows strong HbA1c and weight loss benefits in phase II trial
Novo Nordisk has announced positive Phase II results for zenagamtide, an investigational once-weekly subcutaneous therapy for adults with…
Novo Nordisk’s Investigational Zenagamtide Shows 14.6% Weight Loss In Adults With Type-2 Diabetes
Novo Nordisk’s investigational drug, zenagamtide, has demonstrated an average weight loss of up to 14.6% in individuals with…
Novo Nordisk’s zenagamtide shows 14.6% weight-loss in mid-stage diabetes study, ETPharma
Plainsboro: Novo Nordisk’s next-generation weight-loss candidate, zenagamtide has delivered an average weight-loss of up to 14.6 per cent…
Novo Nordisk’s Mixed Bag: Zenagamtide Data Delights, CagriSema Stumbles, Veru Deal Emerges
Novo Nordisk stock fell 4.4% on CagriSema’s weight loss gap vs Lilly; Zenagamtide slashed HbA1c 1.71% in Phase…
Novo Nordisk’s Pipeline Showdown: Can CagriSema and Zenagamtide Reverse the Stock’s Slide?
Novo Nordisk unveils CagriSema Phase 3 data at ADA after stock drop; oral Wegovy pill shows strong early…
Novo Nordisk’s Pipeline Crossroads: CagriSema, Zenagamtide and EU Wins Put Stock Under the Microsc
Novo Nordisk unveils CagriSema Phase 3 data (1.91% HbA1c drop, 14.2% weight loss) and Zenagamtide Phase 2 at…
Novo Nordisk Repurposes $1.3B Factory Into Warehouse While Zenagamtide Opens New Obesity Frontiers
Novo Nordisk abandons a $1.3B Odense plant for rare diseases, converting it to a warehouse as Wegovy and…
Novo Nordisk’s new weight loss treatment inferior to tirzepatide
Novo Nordisk’s latest weight loss treatment, CagriSema, did not meet the primary endpoint of showing non-inferiority compared to…